Althea Technologies, Inc.
http://www.altheatech.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Althea Technologies, Inc.
Rising Up In Biopharma: Optimism, AI And Perseverance
Ahead of In Vivo’s 2024 Rising Leaders list being revealed in April, a panel of biopharma leaders discussed industry trends and biopharma career stories at BIO-Europe Spring.
Alvotech Willing And Able To Go Stride For Stride On Pembrolizumab Manufacturing
Alvotech stepped into its 2023 annual financing results call bursting with positive news and momentum, on the back of obtaining USFDA approval for its biosimilar Humira product and a bullish outlook for its strong pipeline of biosimilar candidates.
Aurobindo One Step Closer To Xolair Biosimilar Registration
With originator Xolair’s patents already expired or about to end next year, Aurobindo’s CuraTeQ is on track with its omalizumab biosimilar for regulatory filings in 2024/2025, following a Phase I trial completion.
Quantum Outperforms Classical Computer, Finding New KRAS Inhibitors
In a breakthrough for drug discovery, quantum hardware outperformed classical hardware in generating two promising KRAS inhibitors.
Company Information
- Other Names / Subsidiaries
-
- Altus Pharmaceuticals Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice